Announcements Trials
Browse Landscape

Status

Completed 4

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 91Observational 4Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 2Breast 2CNS 1

Conditions

Neoplasms 3Breast Neoplasms 2Brain Neoplasms 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Lapatinib × Clear all
NCT01332396 2017-04-26

Drug Use Investigation for TYKERB Tablet (All Case Investigation)

Novartis

Completed
4,054 enrolled
Tumor-Agnostic

Neoplasms

NCT01782651 2015-08-10

Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients

GlaxoSmithKline

Completed
1 enrolled
Breast

Breast Neoplasms

NCT00975988 2014-10-27

Regulatory TYKERB® Tablets PMS

GlaxoSmithKline

Completed
750 enrolled
Tumor-Agnostic

Neoplasms

NCT01077648 2014-05-26

Brain Metastasis in Breast Cancer Patients

GlaxoSmithKline

Completed
1 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡